title: Personalized medicine - the promised land: are we there yet?
abstract: The delivery of personalized genomic medicine (refer Table 1 for a comparison of genomic vs genetic medicine and box 1 for glossary) hinges on obtaining personal genomic data through genome-wide association studies (GWAS) or whole-genome sequencing. After the completion of the human genome project (see box 2 for human genome projects and its derivative projects) in 2003, there appeared to be a period of euphoric optimism that as soon as the cost of sequencing the whole human genome could be brought down to an affordable range, the promise of personalized medicine would become a reality. However, inasmuch as the miraculous technological advancements are making whole-genome data acquisition an inexpensive reality, we are also starting to appreciate that making sense of the enormous amount of genomic data is a far bigger hurdle. Issues, both scientific and ethico-legal, will have to be addressed as genomic data are been pushed for clinical and direct-to-consumer utilization. [Table: see text].
authors.affiliation: Clinical Genetics Program, Department of Pediatrics, McMaster University Medical Center, Hamilton, Canada. lichum@mcmaster.ca
authors.forename: C
authors.initials: C
authors.lastname: Li
mesh_terms: D005820:Genetic Testing; D015894:Genome, Human; D055106:Genome-Wide Association Study; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods; D057285:Precision Medicine / Q000639:trends*